Expand ATOS Menu
ATOS MENU

ATOS Latest Press Releases

-- December 11, 2025 --

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy PRNewswire 8:00 AM

-- December 9, 2025 --

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen PRNewswire 8:00 AM

-- December 4, 2025 --

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum PRNewswire 8:00 AM

-- December 2, 2025 --

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma PRNewswire 8:00 AM

-- November 17, 2025 --

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation PRNewswire 9:07 AM

-- November 12, 2025 --

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PRNewswire 8:15 AM

-- October 21, 2025 --

Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents PRNewswire 8:00 AM

-- October 15, 2025 --

Atossa Therapeutics to Present at the Maxim Growth Summit 2025 PRNewswire 8:01 AM

-- October 14, 2025 --

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness PRNewswire 8:01 AM

-- October 13, 2025 --

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals PRNewswire 8:00 AM

-- October 6, 2025 --

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities PRNewswire 8:00 AM

-- October 1, 2025 --

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones PRNewswire 8:31 AM

-- September 17, 2025 --

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services Globe Newswire 8:00 AM

-- September 8, 2025 --

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction PRNewswire 8:30 AM

-- August 28, 2025 --

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference PRNewswire 8:30 AM

-- August 20, 2025 --

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer PRNewswire 8:30 AM

-- August 12, 2025 --

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update PRNewswire 8:30 AM

-- July 29, 2025 --

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer PRNewswire 7:45 AM
Market Data Delayed 15 Minutes